Roberta James

Roberta James

Auto-generated profile, based on publicly available information

Roberta James

Teladoc Health, Inc

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 December 2020 in JMIR Diabetes
Verified
Journal Article
Open access
JYJessica S Yu
Jessica S Yu
TXTong Xu
Tong Xu
RJRoberta A James
Roberta A James
WLWei Lu
Wei Lu
JHJulia E Hoffman
Julia E Hoffman
Background: Technology is rapidly advancing our understanding of how people with diabetes mellitus experience stress. Objective: The aim of this study was to explore the relationship between stress and sequelae of diabetes mellitus within a unique data set composed of adults enrolled in a digital diabetes management program, Livongo, in order to inform intervention and product development. Methods: Participants included 3263 adults under age 65 who were diagnosed with diabetes mellitus and had access to Livongo through their employer between June 2015 and August 2018. Data were collected at time of enrollment and 12 months thereafter, which included demographic information, glycemic control, presence of stress, diabetes distress, diabetes empowerment, behavioral health diagnosis, and utilization of behavioral health-related medication and services. Analysis of variance and chi-square tests compared variables across groups that were based on presence of stress and behavioral health diagnosis or utilization. Results: Fifty-five percent of participants (1808/3263) reported stress at the time of at least 1 blood glucose reading. Fifty-two percent of participants (940/1808) also received at least 1 behavioral health diagnosis or intervention. Compared to their peers, participants with stress reported greater diabetes distress, lower diabetes empowerment, greater insulin use, and poorer glycemic control. Participants with stress and a behavioral health diagnosis/utilization additionally had higher body mass index and duration of illness. Conclusions: Stress among people with diabetes mellitus is associated with reduced emotional and physical health. Digital products that focus on the whole person by offering both diabetes mellitus self-management tools and behavioral health skills and support can help improve disease-specific and psychosocial outcomes.

1 June 2021 in Journal of Managed Care & Specialty Pharmacy
Verified
Journal Article
Open access
KMKiraat D Munshi
Kiraat D Munshi
KAKyle Amelung
Kyle Amelung
CCCallie S Carter
Callie S Carter
RJRoberta James
Roberta James
BSBimal R Shah
Bimal R Shah
RHRochelle R Henderson
Rochelle R Henderson
BACKGROUND: Medication nonadherence in diabetes is well documented to be associated with inadequate glycemic control. Through remote blood glucose (BG) monitoring, unlimited test strip and lancet supplies, personal coaching, and online access to clinical information and educational resources, diabetes remote monitoring (DRM) programs may provide a solution. OBJECTIVE: To examine the relationship between patient participation in a DRM solution and adherence to oral antidiabetic drugs (OAD). METHODS: A retrospective, propensity score-matched cohort study was conducted using deidentified administrative claims data from a large pharmacy benefit manager. Commercially insured patients aged 18 years or older and having 2 or more 30-day adjusted OAD claims comprised the target sample. Patients enrolled in insurance plans that implemented DRM, who had at least 1 BG check (ever engaged) between April 1, 2015, and March 31, 2018 (exposure) were matched to patients enrolled in insurance plans that did not implement DRM (nonexposure). After a 1:2 matching on baseline demographics, disease burden proxy, total pharmacy out-of-pocket costs, previous adherence and insulin use, nonexposure group participants were assigned the same first BG check date as their matched DRM participants. Medication adherence measured as proportion of days covered (PDC) in the 365 days following first BG check was examined as a continuous and binary outcome measure (PDC > 80% or adherent vs < 80% or nonadherent). Multivariable linear and logistic regression were conducted to examine differential magnitude in adherence and likelihood of being adherent, respectively. RESULTS: The final sample consisted of 6,002 exposure and 12,004 nonexposure group patients. DRM participants who were ever engaged had a 4.5% higher adherence rate (P < 0.001) and 42% higher odds of being adherent (P < 0.001) in the period after engagement compared with non-DRM participants. Sensitivity analyses showed that patients engaged continuously (> 1 BG check per week) for 3, 6, and 12 months had 5.1%, 5.2%, and 6.4% higher adherence rates, respectively (P < 0.001), and 52%, 64%, and 98% higher odds of being adherent, respectively (P < 0.001), compared with non-DRM participants. CONCLUSIONS: The study findings offer evidence that DRM engagement is associated with higher odds of medication adherence. DRM solutions that provide access to glucose test results, personalized coaching, educational resources, and lower testing supply cost can also influence adherence. Our findings have important implications for payers and patients related to improved health outcomes due to higher medication adherence. DISCLOSURES: Funding for this study was provided by Express Scripts. Munshi, Amelung, Carter, and Henderson are employed by Express Scripts. James and Shah are employed by Livongo, which provided the DRM solution.

26 April 2024 in JMIR Formative Research
Verified
Journal Article
Open access
AKArash Khalilnejad
Arash Khalilnejad
RSRuo-Ting Sun
Ruo-Ting Sun
TKTejaswi Kompala
Tejaswi Kompala
SPStefanie Painter
Stefanie Painter
RJRoberta James
Roberta James
YWYajuan Wang
Yajuan Wang
Background: The growth in the capabilities of telehealth have made it possible to identify individuals with a higher risk of uncontrolled diabetes and provide them with targeted support and resources to help them manage their condition. Thus, predictive modeling has emerged as a valuable tool for the advancement of diabetes management. Objective: This study aimed to conceptualize and develop a novel machine learning (ML) approach to proactively identify participants enrolled in a remote diabetes monitoring program (RDMP) who were at risk of uncontrolled diabetes at 12 months in the program. Methods: Registry data from the Livongo for Diabetes RDMP were used to design separate dynamic predictive ML models to predict participant outcomes at each monthly checkpoint of the participants’ program journey (month-n models) from the first day of onboarding (month-0 model) up to the 11th month (month-11 model). A participant’s program journey began upon onboarding into the RDMP and monitoring their own blood glucose (BG) levels through the RDMP-provided BG meter. Each participant passed through 12 predicative models through their first year enrolled in the RDMP. Four categories of participant attributes (ie, survey data, BG data, medication fills, and health signals) were used for feature construction. The models were trained using the light gradient boosting machine and underwent hyperparameter tuning. The performance of the models was evaluated using standard metrics, including precision, recall, specificity, the area under the curve, the F1-score, and accuracy. Results: The ML models exhibited strong performance, accurately identifying observable at-risk participants, with recall ranging from 70% to 94% and precision from 40% to 88% across the 12-month program journey. Unobservable at-risk participants also showed promising performance, with recall ranging from 61% to 82% and precision from 42% to 61%. Overall, model performance improved as participants progressed through their program journey, demonstrating the importance of engagement data in predicting long-term clinical outcomes. Conclusions: This study explored the Livongo for Diabetes RDMP participants’ temporal and static attributes, identification of diabetes management patterns and characteristics, and their relationship to predict diabetes management outcomes. Proactive targeting ML models accurately identified participants at risk of uncontrolled diabetes with a high level of precision that was generalizable through future years within the RDMP. The ability to identify participants who are at risk at various time points throughout the program journey allows for personalized interventions to improve outcomes. This approach offers significant advancements in the feasibility of large-scale implementation in remote monitoring programs and can help prevent uncontrolled glycemic levels and diabetes-related complications. Future research should include the impact of significant changes that can affect a participant’s diabetes management.

3 October 2023 in JMIR Formative Research
Verified
Journal Article
Open access
EDEldin Dzubur
Eldin Dzubur
JYJessica Yu
Jessica Yu
JHJulia Hoffman
Julia Hoffman
SPStefanie Painter
Stefanie Painter
RJRoberta James
Roberta James
BSBimal Shah
Bimal Shah
Background: Evidence-based digital health programs have shown efficacy in being primary tools to improve emotional and mental health, as well as offering supplementary support to individuals undergoing psychotherapy for anxiety, depression, and other mental health disorders. However, information is lacking about the dose response to digital mental health interventions. Objective: The objective of the study was to examine the effect of time in program and program usage on symptom change among individuals enrolled in a real-world comprehensive digital mental health program (myStrength) who are experiencing severe anxiety or depression. Methods: Eligible participants (N=18,626) were adults aged 18 years and older who were enrolled in myStrength for at least four weeks as part of their employee wellness benefit program, who completed baseline, the 2-week, 2-month, and 6-month surveys querying symptoms of anxiety (Generalized Anxiety Disorder–7 [GAD-7]) and depression (Patient Health Questionnaire–9 [PHQ-9]). Linear growth curve models were used to analyze the effect of average weekly program usage on subsequent GAD-7 and PHQ-9 scores for participants with scores indicating severe anxiety (GAD-7≥15) or depression (PHQ-9≥15). All models were adjusted for baseline score and demographics. Results: Participants in the study (N=1519) were 77.4% female (1176/1519), had a mean age of 45 years (SD 14 years), and had an average enrollment time of 3 months. At baseline, participants reported an average of 9.39 (SD 6.04) on the GAD-7 and 11.0 (SD 6.6) on the PHQ-9. Those who reported 6-month results had an average of 8.18 (SD 6.15) on the GAD-7 and 9.18 (SD 6.79) on the PHQ-9. Participants with severe scores (n=506) experienced a significant improvement of 2.97 (SE 0.35) and 3.97 (SE 0.46) at each time point for anxiety and depression, respectively (t=–8.53 and t=–8.69, respectively; Ps<.001). Those with severe baseline scores also saw a reduction of 0.27 (SE 0.08) and 0.25 (SE 0.09) points in anxiety and depression, respectively, for each additional program activity per week (t=–3.47 and t=–2.66, respectively; Ps<.05). Conclusions: For participants with severe baseline scores, the study found a clinically significant reduction of approximately 9 points for anxiety and 12 points for depression after 6 months of enrollment, suggesting that interventions targeting mental health must maintain active, ongoing engagement when symptoms are present and be available as a continuous resource to maximize clinical impact, specifically in those experiencing severe anxiety or depression. Moreover, a dosing effect was shown, indicating improvement in outcomes among participants who engaged with the program every other day for both anxiety and depression. This suggests that digital mental health programs that provide both interesting and evidence-based activities could be more successful in further improving mental health outcomes.


11 October 2026 in medRxiv
Verified
Preprint
Open access
PDF file
RJRoberta James
Roberta James
MKMeeraj Kothari
Meeraj Kothari
EAEllen Almirol
Ellen Almirol
CSChrista-Marie Singleton
Christa-Marie Singleton
GVGeorge Verghese
George Verghese
ELElizabeth Lowden
Elizabeth Lowden
Background: Digital diabetes programs have expanded quickly, but evidence of durable long-term benefit remains limited. In addition, as diabetes treatment guidelines changed to include cardiorenal-protective antihyperglycemics as first-line therapy, the effects of their adoption on glycemic control and program engagement within these programs remain poorly understood. Objective: To characterize longitudinal trends in glycemic control and estimate the extent to which these trends are associated with time-invariant and time-varying domains, among adults with T2D participating in Teladoc Health’s Remote Diabetes Monitoring Program (RDMP). Methods: This was a retrospective, longitudinal cohort study of adults with T2D participating in the Teladoc RDMP from 2021-2025. Domains were split into time-invariant (i.e. demographics and baseline clinical characteristics) and time-varying covariates (e.g. antihyperglycemic treatment complexity/adherence, program utilization/engagement, and adoption of cardiorenal protective antihyperglycemics). Primary outcome was estimated A1c (eA1c), calculated from fasting blood glucose (FBG) measurements captured through cellular-enable smart glucose meters. Longitudinal mixed-effects models were used to estimate adjusted annual trends in eA1c over 5 years, and Gelbach decomposition to quantify statistical contributions across domains. Secondary analyses examined attainment of eA1c <7% using GEE and complementary decomposition methods. Results: A total of 56,754 members with mean age 64.2 (SD 10.4) and 49% female were included in the analysis. Mean eA1c declined by 0.06 percentage points per year (95% CI −0.06 to −0.06) and remained significantly lower after full adjustment for demographic, antihyperglycemic treatment and cardiorenal-protective therapy adherence, and program engagement factors (β=−.04 percentage points/year; 95% CI −.04 to −.03), demonstrating durable glycemic improvement over the five-year study period. The full model attenuated 48.6% of the declining glycemic trend, indicating that glycemic improvements were only partially explained by demographic, treatment, and engagement factors. Gelbach decomposition attributed most of the difference between the base and fully adjusted trends to cardiorenal-protective therapies (170.8%). Program engagement factors contributed an offsetting share of the explained trend (−71.9%), although greater FBG monitoring and application engagement were associated with lower eA1c in adjusted analyses, while treatment history and complexity contributed minimally (1.1%). Adjusted odds of attaining eA1c <7% increased 8.0% annually (OR 1.08; 95% CI 1.07-1.09), corresponding to a 1.21-percentage-point annual increase in probability; adjusted predicted glycemic control increased from 75.2% in 2021 to 80.1% in 2025. Conclusion: In this long-term experience with a large cohort of patients enrolled in a digital diabetes management program, progressive improvement in glycemic control was observed over the five years of follow-up. The pattern of glycemic improvement was consistent regardless of background exposure to GLP1-RAs and SGLT-2is therapies, including in participants who were never exposed to these therapies. These observations support guideline recommendations which include both the use of indicated medical therapies as well as lifestyle modification which can be facilitated with digital monitoring programs.